267 related articles for article (PubMed ID: 29343281)
21. TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain.
Kawamoto T; Ii M; Kitazaki T; Iizawa Y; Kimura H
Eur J Pharmacol; 2008 Apr; 584(1):40-8. PubMed ID: 18299127
[TBL] [Abstract][Full Text] [Related]
22. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
23. Toll-Like Receptor 2, Toll-Like Receptor 4, Myeloid Differentiation Response Gene 88, and Toll-IL-1 Receptor Domain-Containing Adaptor-Inducing Interferon-γ (TRIF) Selectively Regulate Susceptibility of P0
Brunn A; Mihelcic M; Carstov M; Feind L; Wieser EC; Schmidt J; Utermöhlen O; Deckert M
Am J Pathol; 2017 Jan; 187(1):42-54. PubMed ID: 27842213
[TBL] [Abstract][Full Text] [Related]
24. TRAM is required for TLR2 endosomal signaling to type I IFN induction.
Stack J; Doyle SL; Connolly DJ; Reinert LS; O'Keeffe KM; McLoughlin RM; Paludan SR; Bowie AG
J Immunol; 2014 Dec; 193(12):6090-102. PubMed ID: 25385819
[TBL] [Abstract][Full Text] [Related]
25. Toll-like receptor 4 mediates the antitumor host response induced by a 55-kilodalton protein isolated from Aeginetia indica L., a parasitic plant.
Okamoto M; Oh-E G; Oshikawa T; Furuichi S; Tano T; Ahmed SU; Akashi S; Miyake K; Takeuchi O; Akira S; Himeno K; Sato M; Ohkubo S
Clin Diagn Lab Immunol; 2004 May; 11(3):483-95. PubMed ID: 15138173
[TBL] [Abstract][Full Text] [Related]
26. Extracellular HSP60 induces inflammation through activating and up-regulating TLRs in cardiomyocytes.
Tian J; Guo X; Liu XM; Liu L; Weng QF; Dong SJ; Knowlton AA; Yuan WJ; Lin L
Cardiovasc Res; 2013 Jun; 98(3):391-401. PubMed ID: 23447644
[TBL] [Abstract][Full Text] [Related]
27. The role of Toll-like receptor 4 signaling pathway in ovarian, cervical, and endometrial cancers.
Lupi LA; Cucielo MS; Silveira HS; Gaiotte LB; Cesário RC; Seiva FRF; de Almeida Chuffa LG
Life Sci; 2020 Apr; 247():117435. PubMed ID: 32081661
[TBL] [Abstract][Full Text] [Related]
28. M2000 (β-D-Mannuronic Acid) as a Novel Antagonist for Blocking the TLR2 and TLR4 Downstream Signalling Pathway.
Aletaha S; Haddad L; Roozbehkia M; Bigdeli R; Asgary V; Mahmoudi M; Mirshafiey A
Scand J Immunol; 2017 Feb; 85(2):122-129. PubMed ID: 27943385
[TBL] [Abstract][Full Text] [Related]
29. Expression and function of Toll-like receptors in peripheral blood mononuclear cells from patients with ovarian cancer.
Zhang X; Xu J; Ke X; Zhang S; Huang P; Xu T; Huang L; Lou J; Shi X; Sun R; Wang F; Pan S
Cancer Immunol Immunother; 2015 Mar; 64(3):275-86. PubMed ID: 25376541
[TBL] [Abstract][Full Text] [Related]
30. Recipient Toll-like receptors contribute to chronic graft dysfunction by both MyD88- and TRIF-dependent signaling.
Wang S; Schmaderer C; Kiss E; Schmidt C; Bonrouhi M; Porubsky S; Gretz N; Schaefer L; Kirschning CJ; Popovic ZV; Gröne HJ
Dis Model Mech; 2010; 3(1-2):92-103. PubMed ID: 20038715
[TBL] [Abstract][Full Text] [Related]
31. TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells.
Sun NK; Huang SL; Chang TC; Chao CC
J Cell Physiol; 2018 Mar; 233(3):2489-2501. PubMed ID: 28771725
[TBL] [Abstract][Full Text] [Related]
32. Pathogen-associated molecular patterns initiate inflammation and perturb the endocrine function of bovine granulosa cells from ovarian dominant follicles via TLR2 and TLR4 pathways.
Price JC; Bromfield JJ; Sheldon IM
Endocrinology; 2013 Sep; 154(9):3377-86. PubMed ID: 23825132
[TBL] [Abstract][Full Text] [Related]
33. The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-κB signaling pathway.
He S; Niu G; Shang J; Deng Y; Wan Z; Zhang C; You Z; Shen H
J Exp Clin Cancer Res; 2017 Oct; 36(1):137. PubMed ID: 28978336
[TBL] [Abstract][Full Text] [Related]
34. Spinal toll-like receptor 4-mediated signalling pathway contributes to visceral hypersensitivity induced by neonatal colonic irritation in rats.
Chen ZY; Zhang XW; Yu L; Hua R; Zhao XP; Qin X; Zhang YM
Eur J Pain; 2015 Feb; 19(2):176-86. PubMed ID: 24842692
[TBL] [Abstract][Full Text] [Related]
35. Effects of P-MAPA immunomodulator on Toll-like receptor 2, ROS, nitric oxide, MAPKp38 and IKK in PBMC and macrophages from dogs with visceral leishmaniasis.
Melo LM; Perosso J; Almeida BF; Silva KL; Somenzari MA; de Lima VM
Int Immunopharmacol; 2014 Feb; 18(2):373-8. PubMed ID: 24374021
[TBL] [Abstract][Full Text] [Related]
36. Escherichia coli maltose-binding protein (MBP) activates mouse Th1 through TLR2-mediated MyD88-dependent pathway and TLR4-mediated TRIF-dependent pathway.
Liu G; Zhang Y; Zhang N; Ni W; Jie J; Jiang L; Tai G
Int Immunopharmacol; 2017 Sep; 50():338-344. PubMed ID: 28750349
[TBL] [Abstract][Full Text] [Related]
37. Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer.
De Stefano I; Zannoni GF; Prisco MG; Fagotti A; Tortorella L; Vizzielli G; Mencaglia L; Scambia G; Gallo D
Gynecol Oncol; 2011 Sep; 122(3):573-9. PubMed ID: 21665249
[TBL] [Abstract][Full Text] [Related]
38. Influence of gonadotropin-releasing hormone agonist on the effect of chemotherapy upon ovarian cancer and the prevention of chemotherapy-induced ovarian damage: an experimental study with nu/nu athymic mice.
Lin QY; Wang YF; Weng HN; Sheng XJ; Jiang QP; Yang ZY
J Zhejiang Univ Sci B; 2012 Nov; 13(11):894-903. PubMed ID: 23125082
[TBL] [Abstract][Full Text] [Related]
39. The role of Toll-like receptor 4 in high-glucose-induced inflammatory and fibrosis markers in human peritoneal mesothelial cells.
Choi SY; Ryu HM; Choi JY; Cho JH; Kim CD; Kim YL; Park SH
Int Urol Nephrol; 2017 Jan; 49(1):171-181. PubMed ID: 27722989
[TBL] [Abstract][Full Text] [Related]
40. Synergism of toll-like receptor 2 (TLR2), TLR4, and TLR6 ligation on the production of tumor necrosis factor (TNF)-alpha in a spontaneous arthritis animal model of interleukin (IL)-1 receptor antagonist-deficient mice.
Jung YO; Cho ML; Lee SY; Oh HJ; Park JS; Park MK; Park MJ; Ju JH; Kim SI; Park SH; Kim HY; Min JK
Immunol Lett; 2009 Apr; 123(2):138-43. PubMed ID: 19428561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
